Baseline characteristics and treatments of LVV patients with confirmed or probable COVID-19
| Sex | Age | LVV type | LVV duration (months) | LVV activity | Current LVV therapies | Previous LVV therapies | Comorbidities | COVID-19 Infection | Contact with COVID-19 patient | Onset of COVID-19 symptom | Symptoms | Pneumonia / oxygen | Severity | Treatment changes | Therapies for COVID-19 | Outcome | |
| 1 | M | 75 | GCA | 3 | Remission (<3 months) | Prednisone MTX | No | Concomitant haemopathy (lymphoma) | Confirmed (nasal PCR+ and thoracic CT scan) | Yes (previous hospitalisation 2 weeks before) | 1 March | Fever, fatigue, cough | Yes/no | Hospitalised (1 day) | Discontinuation of MTX and decrease glucocorticoids | Antibiotics | Recovery |
| 2 | F | 87 | GCA | 22 | Remission (≥3 months) | Prednisone MTX | Prednisone MTX | Hypertension, diabetes, cardiovascular disease | Confirmed (nasal PCR+ and thoracic CT scan) | Yes (husband) | 25 March | Fever, fatigue, weight loss, myalgia, cough, diarrhoea, dyspnoea | Yes/yes | Hospitalised (12 days) | No | Antibiotics | Recovery |
| 3 | F | 70 | GCA | 52 | Remission (≥3 months) | Prednisone | Prednisone | Hypertension, asthma | Confirmed (serology) | No | 28 March | Fatigue, myalgia, cough, rhinorrhoea, sore throat, diarrhoea, dyspnoea, pain chest, malaise | No/no | Ambulatory | No | Antibiotics | Recovery |
| 4 | M | 69 | GCA | 46 | Remission (≥3 months) | Prednisone | Prednisone | Hypertension, diabetes | Confirmed (serology) | Yes (wife) | 15 March | Fever, weight loss, sore throat | No/no | Ambulatory | No | Antibiotics | Recovery |
| 5 | F | 19 | TAK | 76 | Remission (≥3 months) | MTX Tocilizumab | Prednisone MTX Tocilizumab | No | Confirmed (nasal PCR+) | Yes (professional) | 15 March | Fever, fatigue, myalgia, sore throat, nausea, diarrhoea, dyspnoea, pain chest, headache | No/no | Ambulatory | Discontinuation of tocilizumab (1 week) | No | Recovery |
| 6 | M | 57 | TAK | 94 | Remission (≥3 months) | Prednisone | Prednisone MTX Tocilizumab Infliximab Everolimus | Hypertension, diabetes, cardiovascular disease, B lymphoma (>1 year) | Confirmed (thoracic CT scan) | Yes (multiple hospitalisation) | 25 March | Fatigue, dyspnoea | Yes/yes (ICU and mechanical ventilation) | Hospita lised (5 days) | No | Antibiotics Hydroxychroquine ICU and mechanical ventilation | Death (1 April) |
| 7 | M | 31 | TAK | 16 | Remission (≥3 months) | Prednisone MTX Tocilizumab | Prednisone | No | Confirmed (serology) | No | 18 March | Fever, fatigue, weight loss, myalgia, rhinorrhoea, anosmia, ageusia, sore throat, dyspnoea, pain chest, nausea, headache | No/no | Ambulatory | No | No | Recovery |
| 8 | F | 44 | TAK | 316 | Remission (≥3 months) | Prednisone | Prednisone AZA | Hypertension, interstitial lung disease | Confirmed (serology) | Yes (professional) | 12 March | Fever, fatigue, myalgia, rhinorrhoea, anosmia and ageusia | No/no | Ambulatory | No | No | Recovery |
| All |
F 4
M 4 | 63 (41–71) |
GCA: 4
TAK: 4 | 49 (21–81) |
R>3 months: 7
R<3 months: 1 |
Prednisone: 7
MTX: 4 Tocilizumab: 2 |
Prednisone: 7
MTX: 3 Tocilizumab: 2 |
Hypertension: 5
Diabetes: 3 Cancer: 2 |
PCR+: 3
Thoracic CT scan: 3 Serology: 4 | Contact with COVID-19 patient: 6 |
Pneumonia:
3 Oxygen: 2 |
Hospital:
3 Home: 5 | Treatments changes: 2 |
Antibiotic:
5 Hydroxychloroquine: 1 ICU: 1 |
Recovery:
7 Death: 1 |
AZA, azathioprine; F, female; GCA, giant cell arteritis; ICU, intensive care unit; LVV, large vessels vasculitis; M, male; MMF, mycophenolate mofetil; MTX, methotrexate; NA, not available; TAK, Takayasu arteritis.